Novartis' remibrutinib shows positive Phase 3 results in relapsing MS
Novartis reported that its BTK inhibitor remibrutinib met efficacy goals in a Phase 3 trial for relapsing multiple sclerosis, reducing disease progression. The company plans to file for expanded approval next year, aiming to compete with Roche's fenebrutinib.
The Phase 3 readout marks a significant milestone for remibrutinib, a Bruton's tyrosine kinase inhibitor that targets a distinct pathway in the immune response. By meeting its efficacy endpoints, the drug demonstrated a measurable reduction in disease progression among patients with relapsing multiple sclerosis, a form of the condition characterized by acute flare-ups followed by periods of remission.
Novartis now intends to pursue an expanded regulatory filing next year, positioning remibrutinib as a direct challenger to Roche's fenebrutinib, another BTK inhibitor in late-stage development. The competitive race underscores a broader shift in MS treatment toward therapies that may offer more targeted modulation of the underlying inflammatory processes, potentially expanding options for patients who do not respond adequately to existing disease-modifying treatments.
If approved, remibrutinib could broaden the therapeutic landscape for relapsing MS patients, offering an alternative mechanism of action that may benefit those with suboptimal responses to current treatments. Greater competition between Novartis and Roche could also influence pricing and access, potentially easing the financial burden on healthcare systems and patients. However, long-term safety and real-world effectiveness remain to be established, and the drug's ultimate societal impact will depend on regulatory decisions and how it integrates into existing care pathways.